Technology
BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress
Published
9 months agoon
By
STOCKHOLM, Feb. 29, 2024 /PRNewswire/ — BioArctic AB (publ) (STO: BIOA-B) today announced that the company and its partner Eisai will present new data on lecanemab (brand name: Leqembi®) at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™), to be held in Lisbon, Portugal and virtually, March 5-9. In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic’s founder Professor Lars Lannfelt.
Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai, and the anti-amyloid beta (Aβ) protofibril antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer’s disease.
At AD/PD, BioArctic will present one oral presentation and one poster on lecanemab, both focused on the binding properties of lecanemab to various types of Aβ of lecanemab compared to several other Aβ antibodies. The company will also have two other posters related to Alzheimer’s disease.
In addition to BioArctic’s presentations, Eisai will present four oral presentations on lecanemab results. From the Phase 3 Clarity AD study in early Alzheimer’s disease[1] with confirmed brain Aβ accumulation, data will include the effect of lecanemab treatment on tau[2] accumulation in whole brain regions, and outcomes of long-term efficacy of lecanemab. In addition, the differences in the binding properties of multiple anti-amyloid (Aβ) antibodies to various types of Aβ and other data will be presented.
Eisai will also sponsor a symposium featuring three prominent clinical experts in the field of Alzheimer’s disease, Dr. Jeffrey Cummings, Dr. Robert Perneczky and Dr. Miia Kivipelto. Dr. Jeffrey Cummings will chair the symposium, and provide an overview of meaningful benefits, including clinical meaningfulness and the evolution of approaches for the clinical study of Alzheimer’s disease. Dr. Robert Perneczky will discuss how to assess meaningful benefits of treatments in development for Alzheimer’s disease. Dr. Miia Kivipelto’s presentation will provide new statistical methods to measure meaningful benefits and address various stakeholder perspectives.
Furthermore, Eisai’s Chief Clinical Officer, Lynn Kramer, M.D., will give a plenary presentation titled “Novel approaches to clinical development and the future potential of simulated placebo” on March 7 at the “Aβ TARGETING THERAPIES IN AD 1” session.
Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for a joint commercialization in the region.
Presentations by BioArctic and Eisai
Oral presentations
Asset in Development, Session, Time
Presentation Title
Lecanemab
Abeta Targeting Therapies in AD 01
Thursday, March 7, 13:50 – 14:05
Treatment with lecanemab disrupts tau accumulation across brain regions in early Alzheimer’s disease
Lecanemab
Abeta Targeting Therapies in AD 02
Saturday, March 9, 8:40 – 8:55
Binding characteristics of lecanemab, donanemab and other amyloid-beta antibodies to different forms of amyloid-beta in Alzheimer’s disease brains
Presented by BioArctic
Lecanemab
Abeta Targeting Therapies in AD 02
Saturday, March 9, 9:10 – 9:25
Lecanemab for the treatment of early Alzheimer’s disease: the extension of efficacy results from Clarity AD
Lecanemab
Abeta Targeting Therapies in AD 02
Saturday, March 9, 9:25-9:40
Structural dynamics of amyloid-β protofibrils and action of lecanemab as observed by high-speed atomic force microscopy
Lecanemab
Virtual Oral Presentation
VO028 / #2922
A neuro-dynamic quantitative systems pharmacology (QSP) model for Alzheimer’s disease incorporating amyloid and tau pathophysiology
Poster presentations
Asset in Development, Topic, Poster Number
Presentation Title
Lecanemab
P0213 / #1510
March 8 to 9
Characterization of amyloid-beta species in Alzheimer’s disease brain and the unique binding properties of lecanemab
Presented by BioArctic
General AD
P0110 / #562
March 8 to 9
Increased level of 12 KDA C-terminal ApoE fragments in AD brainPresented by BioArctic
General AD
P0111 / #943
March 8 to 9
Functional and morphological effects of 12 KDA C-terminal ApoE fragments in rat cortex culturesPresented by BioArctic
Eisai-Sponsored Symposium
Time
Title, Presenter
Thursday, March 7, 11:10 – 12:50
Defining meaningful benefits to patients, caregivers, and healthcare systems in Alzheimer’s diseaseJeffrey Cummings, Robert Perneczky, Miia Kivipelto,
Plenary presentation
Session, Time
Title
Abeta Targeting Therapies in AD 01
Thursday, March 7, 15:20 – 15:35
Novel approaches to clinical development and the future potential of simulated placebo
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.
The information was released for public disclosure, through the agency of the contact persons below, on February 29, 2024, at 08.00 a.m. CET.
For further information, please contact:
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
Jiang Millington, Director Corporate Communication and Social Media
E-mail: jiang.millington@bioarctic.se
Phone: +46 79 33 99 166
About lecanemab (generic name, U.S., Japan and China brand name: Leqembi®)
Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). In the U.S., Leqembi was granted traditional approval by the US Food and Drug Administration (FDA) on July 6, 2023. Leqembi is indicated as a disease-modifying treatment for Alzheimer’s disease (AD) in the US. Treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Please see full U.S. Prescribing Information.
In Japan, Eisai received approval from the Ministry of Health, Labour and Welfare (MHLW) on September 25, 2023, to manufacture and market lecanemab as a treatment for slowing progression of MCI and mild dementia due to AD. Furthermore, in China, Leqembi was approved by the National Medical Products Administration (NMPA) as a treatment of MCI due to AD and mild AD dementia in January 2024.
Eisai has also submitted applications for approval of lecanemab in 14 different countries, including EU, Canada and Great Britain.
Eisai has completed a lecanemab subcutaneous bioavailability study, and subcutaneous dosing is currently being evaluated in the Clarity AD (Study 301) open-label extension (OLE) study. A maintenance dosing regimen has been evaluated as part of the Phase 2b study (Study 201).
Since July 2020 Eisai’s Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health and Eisai.
Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer’s disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer’s disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease. Several of the projects utilize the company’s proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic’s B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se.
[1] Early Alzheimer’s disease includes mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease
[2] A protein that aggregates intracellularly in nerve cells in Alzheimer’s disease, disrupting both the function and survival of the cell. Tau levels can be measured in plasma, cerebrospinal fluid, and with a positron camera (PET).
The following files are available for download:
https://mb.cision.com/Main/9978/3937731/2636450.pdf
Latest data on lecanemab to be presented at the 2024 AD/PDâ„¢ congress
View original content:https://www.prnewswire.co.uk/news-releases/bioarctic-latest-data-on-lecanemab-to-be-presented-at-the-2024-adpd-congress-302075416.html
You may like
Technology
Avathon Partners with CP PLUS, Largest CCTV Manufacturer in India, to Enhance Public Safety while Strengthening Community Bonds
Published
36 minutes agoon
November 14, 2024By
PLEASANTON, Calif., Nov. 13, 2024 /PRNewswire/ — Avathon, provider of the leading AI platform for industrial operations, has partnered with CP PLUS, one of the largest manufacturers of CCTV cameras, to create safer, more connected societies by bundling Avathon’s computer vision technology with each camera. The companies are bringing Avathon’s computer vision AI capabilities to small and medium-sized businesses (SMBs) across India, turning their cameras into intelligent assets that enable more secure workplaces, factories and facilities.
In today’s fast-paced world, it’s hard to keep an eye on every single detail, every minute of the day. Computer vision AI technology gives users the freedom and control to go about their daily lives knowing they will receive proactive alerts identifying safety and security issues in real time.
“Increasing demand for advanced public safety tools, smart home devices and integrated AI-powered cameras is fueling massive industry growth,” said Aditya Khemka, Managing Director, CP PLUS, a subsidiary of Aditya Group. “Our partnership with Avathon will help us to better deliver state-of-the-art AI-powered solutions that feature advanced functions like real-time anomaly detection and intelligent monitoring.”
Avathon’s computer vision AI automatically detects and alerts unsafe conditions and incidents in real time, allowing users to proactively take the right actions. Avathon enables business owners using valuable resources to monitor CCTV camera feeds to get back to focusing on operations. The company partners with OEM camera manufacturers by providing AI technology that enables end customers to quickly and accurately address processes, behaviors, and conditions that cause unacceptable risk. Through its partnership with CP PLUS, Avathon has democratized this technology, giving access to large organizations and small businesses alike.
CP PLUS is India’s leading surveillance brand with the most extensive portfolio in the entire global industry. Representing a major share of the Indian CCTV market, CP PLUS offers a range of products and services to meet the varied needs of government, commercial, residential, and industrial customers and its products are successfully deployed in every nook and corner of India and many countries across verticals and industry.
“AI cameras are paving the path forward in India toward smart-city initiatives and enhanced public safety improvements. In this sometimes disconnected world, it’s comforting to rely on a technology that instantly alerts users to potential dangers and other anomalies,” said Pervinder Johar, CEO of Avathon. “We’re proud to partner with CP PLUS to provide the AI innovations needed to push India to the leading edge of technological advancement.”
About Avathon
Avathon, a leader in Industrial AI, extends the life of critical infrastructure while advancing the journey toward full autonomy. Avathon’s Industrial AI platform empowers commercial and government customers with scalable, secure, and value-driven solutions that enhance efficiency and resilience across heavy industry.
Media contact:
Jon Ross
Sr. PR & Communications Manager
Avathon
jross@avathon.com
View original content:https://www.prnewswire.com/news-releases/avathon-partners-with-cp-plus-largest-cctv-manufacturer-in-india-to-enhance-public-safety-while-strengthening-community-bonds-302304865.html
SOURCE Avathon
Technology
Belgian Unicorn Odoo Celebrates Remarkable First Anniversary in Indonesia
Published
36 minutes agoon
November 14, 2024By
JAKARTA, Indonesia, Nov. 14, 2024 /PRNewswire/ — This November, Belgian business management software company Odoo celebrates 1st anniversary of the Indonesian office with esteemed partners and customers like Ismaya, Pertamina Energy Terminal, DORÉ, Dekoruma, Abuba Steak, Perum Bulog and Arista Group, to name a few.
With a mission to help more businesses to become digitally organized, the software company started actively developing the Indonesian market five years ago and has reached record-breaking milestones one after another—91.2% average annual growth and a quadrupled 189 active local partners—making Indonesia the best-performing market in APAC for six consecutive years.
The now locally based Odoo Indonesia is confident in extending services and helping businesses of all sizes in the country to digitally transform business management to contribute to optimized workflow efficiency and national economic growth.
To support rapid market expansion, Odoo will base its operations in BSD as the area embodies the start-up environment the Belgian firm always strives for—vibrant & dynamic—a choice affirmed by its sustained success in digital transformation endeavors across Indonesia.
Odoo opens first SEA office in BSD.
From a squad of 3, Odoo Indonesia has expanded into an over 80-strong team. In 2024, it engaged the community at 41 events in major cities, including Medan, Bandung, Surabaya, and Makassar, and around the archipelago in Java, Sumatra, Kalimantan, and Sulawesi, providing countless on-site support. Within a year of opening, the company introduced multiple landmark integrations and regionalized upgrades.
Odoo-Xendit Integration
Integration with Indonesian-based payment solution provider Xendit is made standard in Odoo to facilitate effortless transactions in Indonesia and across Southeast Asia through QRIS, e-Wallets, convenience stores, and other major payment methods in the region.
e-Faktur Submission
To support the Tax Office e-Faktur application, Odoo now collects necessary data to automate documents to assist users in completing the submission process in compliance with local regulations and is in the last stages of integrating with Pajak.io for direct submission from Odoo.
QRIS Features
The team introduced QRIS into the system to maximize ways to receive payments, facilitating a more convenient and localized payment process for Indonesian Odoo users.
Odoo-Shopee Integration
In October, Odoo announced upcoming integration with Shopee, the leading eCommerce platform in Southeast Asia.
“The opening of Odoo’s new office in BSD marks a significant milestone in our effort to penetrate the Indonesia market. Looking at our journey so far, I am also extremely proud of my team for their relentless contributions in helping our customers become more efficient, one app at a time. Moving forward, we aim to expand the team even more and the best part is: we are always looking for top talents to join us!” — Benny Putra Sugito, Director of Odoo (Indonesia)
Odoo is committed to leading the Indonesian business scene. While its expansion also aims to generate employment opportunities to offer the country a professional workforce in tech and business management, Odoo is resolute in educating the market about the significance of utilizing the right business tools and is dedicated to offering a comprehensive and integrable yet approachable solution to facilitate an easy digital transformation process for 64.2 million businesses of all sizes in Indonesia.
About Odoo
Odoo is a Belgian online business management software with a complete suite of business modules. The open-source service provider operates in 19 locations worldwide, including Indonesia, the United States, Hong Kong SAR, and Dubai. With 80+ official apps and 49k+ third-party apps, Odoo manages businesses’ finance, sales, inventory & manufacturing processes, human resources, marketing, team productivity, and more.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/belgian-unicorn-odoo-celebrates-remarkable-first-anniversary-in-indonesia-302305086.html
SOURCE PT Odoo Software Indonesia
Technology
ZEEKR Reports Third Quarter 2024 Unaudited Financial Results
Published
36 minutes agoon
November 14, 2024By
HANGZHOU, China, Nov. 14, 2024 /PRNewswire/ — ZEEKR Intelligent Technology Holding Limited (“ZEEKR” or the “Company”) (NYSE: ZK), a global premium electric mobility technology company, today announced its unaudited financial results for the third quarter ended September 30, 2024.
Operating Highlights for the Third Quarter of 2024
Total vehicle deliveries were 55,003 units for the third quarter of 2024, representing a 51% year-over-year increase.
Deliveries
2024 Q3
2024 Q2
2024 Q1
2023 Q4
55,003
54,811
33,059
39,657
Deliveries
2023 Q3
2023 Q2
2023 Q1
2022 Q4
36,395
27,399
15,234
32,467
Financial Highlights for the Third Quarter of 2024
Vehicle sales were RMB14,401.3 million (US$2,052.2 million)[1] for the third quarter of 2024, representing an increase of 42.0% from the third quarter of 2023 and an increase of 7.2% from the second quarter of 2024.
Vehicle margin[2] was 15.7% for the third quarter of 2024, compared with 18.1% for the third quarter of 2023 and 14.2% for the second quarter of 2024.
Total revenues were RMB18,358.0 million (US$2,616.0 million) for the third quarter of 2024, representing an increase of 30.7% from the third quarter of 2023 and a decrease of 8.4% from the second quarter of 2024.
Gross profit was RMB2,941.8 million (US$419.2 million) for the third quarter of 2024, representing an increase of 28.5% from the third quarter of 2023 and a decrease of 14.7% from the second quarter of 2024.
Gross margin was 16.0% for the third quarter of 2024, compared with 16.3% for the third quarter of 2023 and 17.2% for the second quarter of 2024.
Loss from operations was RMB1,216.4 million (US$173.3 million) for the third quarter of 2024, representing a decrease of 19.3% from the third quarter of 2023 and a decrease of 29.3% from the second quarter of 2024. Excluding share-based compensation expenses, adjusted loss from operations (non-GAAP)[3] was RMB1,169.8 million (US$166.7 million) for the third quarter of 2024, representing a decrease of 20.8% from the third quarter of 2023 and an increase of 50.5% from the second quarter of 2024.
Net loss was RMB1,139.1 million (US$162.3 million) for the third quarter of 2024, representing a decrease of 21.7% from the third quarter of 2023 and a decrease of 37.0% from the second quarter of 2024. Excluding share-based compensation expenses, adjusted net loss (non-GAAP) was RMB1,092.6 million (US$155.7 million) for the third quarter of 2024, representing a decrease of 23.4% from the third quarter of 2023 and an increase of 26.3% from the second quarter of 2024.
[1] All conversions from Renminbi(“RMB”) to U.S. dollars (“US$”) are made at an exchange rate of RMB7.0176 to US$1.00, set forth in the H.10 statistical release of the Federal Reserve Board on September 30, 2024.
[2] Vehicle margin is the margin of vehicle sales, which is calculated based on revenues and cost of revenues derived from vehicle sales only.
[3] The Company’s non-GAAP financial measures exclude share-based compensation expenses. See “Unaudited Reconciliation of GAAP and Non-GAAP Results” set forth at the end of this announcement.
Key Financial Results
(in RMB millions, except for percentages)
2024 Q3
2024 Q2
2023 Q3
% Change i
YoY
QoQ
Vehicle sales
14,401.3
13,438.2
10,143.7
42.0 %
7.2 %
Vehicle margin
15.7 %
14.2 %
18.1 %
(2.4)pts
1.5pts
Total revenues
18,358.0
20,040.1
14,044.6
30.7 %
(8.4) %
Gross profit
2,941.8
3,449.8
2,289.4
28.5 %
(14.7) %
Gross margin
16.0 %
17.2 %
16.3 %
(0.3)pts
(1.2)pts
Loss from operations
(1,216.4)
(1,721.0)
(1,507.8)
(19.3) %
(29.3) %
Non-GAAP loss from operations
(1,169.8)
(777.1)
(1,477.6)
(20.8) %
50.5 %
Net loss
(1,139.1)
(1,808.8)
(1,455.7)
(21.7) %
(37.0) %
Non-GAAP net loss
(1,092.6)
(864.9)
(1,425.6)
(23.4) %
26.3 %
i
Except for vehicle margin and gross margin, absolute changes instead of percentage changes are presented.
Recent Developments
Delivery Update
In October 2024, the Company delivered 25,049 vehicles, representing an increase of 92% from October 2023.
New Model Launches
On October 23, 2024, ZEEKR officially launched and commenced deliveries of the ZEEKR MIX, a five-seat, family-oriented vehicle. The ZEEKR MIX redefines the concept of an everyday driver, seamlessly combining ample space, outstanding safety, and agile handling. As the first model built on the Company’s SEA-M architecture, the ZEEKR MIX boasts up to 93% in-cabin space utilization, maximizing interior space through innovative packaging and a capsule-style exterior. Two front-row seats that can swivel 270 degrees and a movable central console enhance cabin versatility, enabling “9+N” cabin scenario modes and flexible seating arrangements.
CEO and CFO Comments
“Our performance remained strong and resilient this quarter, marked by record-high deliveries and successful new model launches,” said Mr. Andy An, ZEEKR’s chief executive officer. “In the third quarter, we set a new record with 55,003 vehicle deliveries, representing a 51% year-over-year increase, and reached an additional milestone in October with monthly deliveries of 25,049 units. Notably, the ZEEKR 7X’s deliveries exceeded 20,000 units within 50 days since its launch, marking a robust achievement in the highly competitive mainstream SUV market. As we expand our product lineup and strengthen each model’s position in its respective category, we are delivering ZEEKR’s ultimate driving experience to more users, further cementing ZEEKR’s industry leadership.”
Mr. Jing Yuan, ZEEKR’s chief financial officer, added, “Our disciplined cost control measures, coupled with ongoing optimization of product structure, economies of scale, and technological innovation, drove a 30.7% year-over-year increase in revenue. Vehicle sales for the quarter grew by 42.0% and 7.2% year-over-year and quarter-over-quarter, respectively. Meanwhile, vehicle margin remained on an upward trajectory, rising to 15.7% in the third quarter of 2024, highlighting our consistent progress in profitability enhancement. Looking ahead, we will continue to consolidate resources, strengthen product capabilities, and expand our industry presence to propel our sustainable growth.”
Financial Results for the Third Quarter of 2024
Revenues
Total revenues were RMB18,358.0 million (US$2,616.0 million) for the third quarter of 2024, representing an increase of 30.7% from RMB14,044.6 million for the third quarter of 2023 and a decrease of 8.4% from RMB20,040.1 million for the second quarter of 2024.
Revenues from vehicle sales were RMB14,401.3 million (US$2,052.2 million) for the third quarter of 2024, representing an increase of 42.0% from RMB10,143.7 million for the third quarter of 2023, and an increase of 7.2% from RMB13,438.2 million for the second quarter of 2024. The year-over-year increase was due to the increase in new product delivery volume, partially offset by the lower average selling price due to the different product mix and pricing strategy changes between the two quarters. The quarter-over-quarter increase was mainly attributable to the launch of the ZEEKR 7X new model in the third quarter of 2024 and the higher average selling price resulting from changes in product mix.
Revenues from sales of batteries and other components were RMB3,245.3 million (US$462.5 million) for the third quarter of 2024, representing a decrease of 1.3% from RMB3,288.8 million for the third quarter of 2023 and a decrease of 38.8% from RMB5,299.2 million for the second quarter of 2024. The revenues from sales of batteries and other components remained relatively stable compared with the third quarter of 2023. The quarter-over-quarter decrease was mainly driven by lower sales volume of battery packs in the domestic market.
Revenues from research and development service and other services were RMB711.4 million (US$101.4 million) for the third quarter of 2024, representing an increase of 16.2% from RMB612.1 million for the third quarter of 2023 and a decrease of 45.4% from RMB1,302.6 million for the second quarter of 2024. The year-over-year increase was mainly due to the increased sales of after-sales vehicle services. The quarter-over-quarter decrease was mainly due to the decreased sales of research and development services to related parties.
Cost of Revenues and Gross Margin
Cost of revenues was RMB15,416.2 million (US$2,196.8 million) for the third quarter of 2024, representing an increase of 31.1% from RMB11,755.2 million for the third quarter of 2023 and a decrease of 7.1% from RMB16,590.2 million for the second quarter of 2024. The year-over-year increase was mainly attributable to the increase in vehicle delivery volume and the quarter-over-quarter decrease was mainly attributable to the decrease in sales of batteries and other components.
Gross profit was RMB2,941.8 million (US$419.2 million) for the third quarter of 2024, representing an increase of 28.5% from RMB2,289.4 million for the third quarter of 2023 and a decrease of 14.7% from RMB3,449.8 million for the second quarter of 2024.
Gross margin was 16.0% for the third quarter of 2024, compared with 16.3% for the third quarter of 2023 and 17.2% for the second quarter of 2024. The gross margin remained relatively stable compared with the third quarter of 2023. The quarter-over-quarter decrease was mainly attributable to the decreased margins on batteries and other components.
Vehicle margin was 15.7% for the third quarter of 2024, compared with 18.1% for the third quarter of 2023 and 14.2% for the second quarter of 2024. The year-over-year decrease was primarily attributed to the lower average selling price of ZEEKR vehicles due to the different product mix and pricing strategy changes between the two quarters, partially offset by the procurement savings as the cost of auto parts and materials decreased. The quarter-over-quarter increase was mainly due to the change in product mix.
Operating Expenses
Research and development expenses were RMB1,966.2 million (US$280.2 million) for the third quarter of 2024, representing a decrease of 2.6% from RMB2,018.1 million for the third quarter of 2023 and a decrease of 25.1% from RMB2,623.5 million for the second quarter of 2024. Research and development expenses remained relatively stable compared with the third quarter of 2023. The quarter-over-quarter decrease was mainly due to a one-off, large quantity of share-based compensation expenses in the second quarter, conditioned on the Company’s initial public offering.
Selling, general and administrative expenses were RMB2,274.8 million (US$324.1 million) for the third quarter of 2024, representing an increase of 25.4% from RMB1,813.9 million for the third quarter of 2023 and a decrease of 12.7% from RMB2,604.7 million for the second quarter of 2024. The year-over-year increase was mainly due to increased expenses related to the expansion of offline channels in China and overseas as well as the marketing activities of the launch of new models. The quarter-over-quarter decrease was mainly due to a one-off, large quantity of share-based compensation expenses in the second quarter, conditioned on the Company’s initial public offering.
Loss from Operations
Loss from operations was RMB1,216.4 million (US$173.3 million) for the third quarter of 2024, representing a decrease of 19.3% from RMB1.507.8 million for the third quarter of 2023 and a decrease of 29.3% from RMB1,721.0 million for the second quarter of 2024.
Non-GAAP loss from operations, which excludes share-based compensation expenses from loss from operations, was RMB1,169.8 million (US$166.7 million) for the third quarter of 2024, representing a decrease of 20.8% from RMB1,477.6 million for the third quarter of 2023 and an increase of 50.5% from RMB777.1 million for the second quarter of 2024.
Net Loss and Net Loss Per Share
Net loss was RMB1,139.1 million (US$162.3 million) for the third quarter of 2024, representing a decrease of 21.7% from RMB1,455.7 million for the third quarter of 2023 and a decrease of 37.0% from RMB1,808.8 million for the second quarter of 2024.
Non-GAAP net loss, which excludes share-based compensation expenses from net loss, was RMB1,092.6 million (US$155.7 million) for the third quarter of 2024, representing a decrease of 23.4% from RMB1,425.6 million for the third quarter of 2023 and an increase of 26.3% from RMB864.9 million for the second quarter of 2024.
Net loss attributable to ordinary shareholders of ZEEKR was RMB1,226.3 million (US$174.7 million) for the third quarter of 2024, representing a decrease of 16.9% from RMB1,476.1 million for the third quarter of 2023 and a decrease of 44.0% from RMB2,190.2 million for the second quarter of 2024.
Non-GAAP net loss attributable to ordinary shareholders of ZEEKR, which excludes share-based compensation expenses from net loss attributable to ordinary shareholders, was RMB1,179.7 million (US$168.1 million) for the third quarter of 2024, representing a decrease of 18.4% from RMB1,445.9 million for the third quarter of 2023 and a decrease of 5.3% from RMB1,246.3 million for the second quarter of 2024.
Basic and diluted net loss per share attributed to ordinary shareholders were RMB0.48 (US$0.07) each for the third quarter of 2024, compared with RMB0.74 each for the third quarter of 2023 and RMB0.95 each for the second quarter of 2024.
Non-GAAP basic and diluted net loss per share attributed to ordinary shareholders were both RMB0.46 (US$0.07) each for the third quarter of 2024, compared with RMB0.72 each for the third quarter of 2023 and RMB0.54 each for the second quarter of 2024.
Basic and diluted net loss per American Depositary Share (“ADS[4]”) attributed to ordinary shareholders were RMB4.80 (US$0.68) each for the third quarter of 2024, compared with RMB9.51 each for the second quarter of 2024.
Non-GAAP basic and diluted net loss per ADS attributed to ordinary shareholders were RMB4.62 (US$0.66) each for the third quarter of 2024, compared with RMB5.41 each for the second quarter of 2024.
[4] Each ADS represents ten ordinary shares.
Balance Sheets
Cash and cash equivalents and restricted cash was RMB8,297.7 million (US$1,182.4 million) as of September 30, 2024.
Conference Call
The Company’s management will host an earnings conference call on Thursday, November 14, 2024, at 7:00 A.M. U.S. Eastern Time (8:00 P.M. Beijing/Hong Kong Time on the same day).
All participants who wish to join the call are requested to complete the online registration using the link provided below. After registration, each participant will receive by email a set of dial-in numbers, a passcode and a unique access PIN to join the conference call. Participants may pre-register at any time, including up to and after the call start time.
Participant Online Registration: https://dpregister.com/sreg/10194063/fdd5d5735e
A live webcast of the conference call will be available on the Company’s investor relations website at https://ir.zeekrlife.com/.
About ZEEKR
ZEEKR (NYSE: ZK) is a global premium electric mobility technology brand from Geely Holding Group. ZEEKR aims to create a fully integrated user ecosystem with innovation as a standard. ZEEKR utilizes Sustainable Experience Architecture (SEA) and develops its own battery technologies, battery management systems, electric motor technologies, and electric vehicle supply chains. ZEEKR’s value is equality, diversity, and sustainability. Its ambition is to become a true mobility solution provider.
ZEEKR operates its R&D centers and design studios in Ningbo, Hangzhou, Gothenburg, and Shanghai and boasts state-of-the-art facilities and world-class expertise. Since ZEEKR began delivering vehicles in October 2021, the brand has developed a diversified product portfolio that primarily includes the ZEEKR 001, a luxury shooting brake; the ZEEKR 001 FR, a hyper-performing electric shooting brake; the ZEEKR 009, a pure electric luxury MPV; the ZEEKR 009 Grand, a four-seat ultra-luxury flagship MPV; the ZEEKR X, a compact SUV; the ZEEKR 7X, a premium electric five-seater SUV; the ZEEKR MIX; and an upscale sedan model. ZEEKR has announced plans to sell vehicles in global markets, and has an ambitious roll-out plan over the next 5 years to satisfy the rapidly expanding global EV demand.
For more information, please visit https://ir.zeekrlife.com/.
Non-GAAP Financial Measures
The Company uses non-GAAP financial measures, such as non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, non-GAAP basic and diluted net loss per ordinary share attributed to ordinary shareholders, non-GAAP basic and diluted net loss per ADS attributed to ordinary shareholders, in evaluating its operating results and for financial and operational decision-making purposes. By excluding the impact of share-based compensation expenses, the Company believes that the non-GAAP financial measures help identify underlying trends in its business and enhance the overall understanding of the Company’s past performance and future prospects. The Company also believes that the non-GAAP financial measures allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making. The non-GAAP financial measures are not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measures have limitations as analytical tools and when assessing the Company’s operating performance, investors should not consider them in isolation, or as a substitute for net loss or other consolidated statements of comprehensive loss data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company’s performance.
For more information on the non-GAAP financial measures, please see the table captioned “Unaudited Reconciliations of GAAP and non-GAAP Results” set forth in this announcement.
Exchange Rate Information
This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB7.0176 to US$1.00, the exchange rate on September 30, 2024, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollar amounts referred to could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “future,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this announcement is as of the date of this announcement, and the Company does not undertake any duty to update such information, except as required under applicable law.
For Investor Enquiries
ZEEKR
Investor Relations
Email: ir@zeekrlife.com
For Media Enquiries
ZEEKR
Media Relations
Email: Globalcomms@zeekrlife.com
ZEEKR INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
As of
December 31
September 30
September 30
2023
2024
2024
RMB
RMB
US$
ASSETS
Current assets:
Cash and cash equivalents
3,260,670
5,640,993
803,835
Restricted cash
844,079
2,656,734
378,582
Notes receivable
487,851
952,108
135,674
Accounts receivable
1,104,450
2,096,355
298,728
Inventories
5,228,689
4,745,085
676,169
Amounts due from related parties
7,256,861
6,535,623
931,319
Prepayments and other current assets
2,294,508
2,711,024
386,317
Total current assets
20,477,108
25,337,922
3,610,624
Property, plant and equipment, net
2,914,274
3,265,370
465,312
Intangible assets, net
410,912
624,404
88,977
Land use rights, net
51,755
62,185
8,861
Operating lease right-of-use assets
2,443,545
2,225,175
317,085
Deferred tax assets
86,395
195,175
27,812
Long-term investments
459,794
629,383
89,686
Other non-current assets
273,717
367,752
52,404
Total non-current assets
6,640,392
7,369,444
1,050,137
TOTAL ASSETS
27,117,500
32,707,366
4,660,761
ZEEKR INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
(Amounts in thousands)
As of
December 31
September 30
September 30
2023
2024
2024
RMB
RMB
US$
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term Borrowings
–
30,000
4,275
Accounts payable
4,104,717
3,589,418
511,488
Notes payable
5,504,945
12,474,151
1,777,552
Amounts due to related parties
16,355,902
15,008,230
2,138,656
Income tax payable
108,083
172,826
24,628
Accruals and other current liabilities
6,243,956
8,114,841
1,156,354
Total current liabilities
32,317,603
39,389,466
5,612,953
Long-term borrowings
–
414,630
59,084
Operating lease liabilities, non-current
1,807,159
1,577,950
224,856
Amounts due to related parties, non-current
1,100,000
–
–
Other non-current liabilities
563,001
540,082
76,961
Deferred tax liability
8,337
8,224
1,172
Total non-current liabilities
3,478,497
2,540,886
362,073
TOTAL LIABILITIES
35,796,100
41,930,352
5,975,026
SHAREHOLDERS’ EQUITY
Ordinary shares
2,584
3,361
479
Convertible preferred shares
362
–
–
Shares subscription receivable
–
(66)
(9)
Additional paid-in capital
11,213,798
15,683,094
2,234,823
Accumulated deficits
(20,865,686)
(26,296,475)
(3,747,218)
Accumulated other comprehensive income/(loss)
17,555
(26,402)
(3,762)
Total ZEEKR shareholders’ deficit
(9,631,387)
(10,636,488)
(1,515,687)
Non-controlling interest
952,787
1,413,502
201,422
TOTAL SHAREHOLDERS’ DEFICIT
(8,678,600)
(9,222,986)
(1,314,265)
TOTAL LIABILITIES AND SHAREHOLDERS’
EQUITY
27,117,500
32,707,366
4,660,761
ZEEKR INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE
(LOSS)/INCOME
(Amounts in thousands, except share/ADS and per share/ADS data and otherwise noted)
Three Months Ended
September 30
June 30
September 30
September 30
2023
2024
2024
2024
RMB
RMB
RMB
US$
Revenues:
Vehicle sales
10,143,742
13,438,241
14,401,309
2,052,170
Sales of batteries and other components
3,288,766
5,299,171
3,245,331
462,456
Research and development service and
other services
612,103
1,302,639
711,362
101,368
Total revenues
14,044,611
20,040,051
18,358,002
2,615,994
Cost of revenues:
Vehicle sales
(8,308,327)
(11,533,020)
(12,146,781)
(1,730,902)
Sales of batteries and other components
(3,050,588)
(4,223,452)
(2,808,646)
(400,229)
Research and development service and
other services
(396,289)
(833,756)
(460,775)
(65,660)
Total cost of revenues
(11,755,204)
(16,590,228)
(15,416,202)
(2,196,791)
Gross profit
2,289,407
3,449,823
2,941,800
419,203
Operating expenses:
Research and development expenses
(2,018,136)
(2,623,471)
(1,966,167)
(280,177)
Selling, general and administrative
expenses
(1,813,890)
(2,604,665)
(2,274,751)
(324,149)
Other operating income, net
34,851
57,287
82,747
11,791
Total operating expenses
(3,797,175)
(5,170,849)
(4,158,171)
(592,535)
Loss from operations
(1,507,768)
(1,721,026)
(1,216,371)
(173,332)
Interest expense
(28,186)
(23,396)
(8,088)
(1,153)
Interest income
27,614
42,537
43,255
6,163
Other income/(expense), net
6,020
(7,809)
54,967
7,833
Loss before income tax expense and
share of losses in equity method
investments
(1,502,320)
(1,709,694)
(1,126,237)
(160,489)
Share of income in equity method
investments
33,021
85,852
81,500
11,614
Income tax benefits/(expense)
13,605
(184,980)
(94,409)
(13,453)
Net loss
(1,455,694)
(1,808,822)
(1,139,146)
(162,328)
Less: income attributable to non-
controlling interest
20,368
381,363
87,134
12,416
Net loss attributable to shareholders
of ZEEKR
(1,476,062)
(2,190,185)
(1,226,280)
(174,744)
ZEEKR INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE
(LOSS)/INCOME (CONTINUED)
(Amounts in thousands, except share/ADS and per share/ADS data and otherwise noted)
Three Months Ended
September 30
June 30
September 30
September 30
2023
2024
2024
2024
RMB
RMB
RMB
US$
Net loss per share attributed to
ordinary shareholders:
Basic and diluted
(0.74)
(0.95)
(0.48)
(0.07)
Weighted average shares used in
calculating net loss per share:
Basic and diluted
2,000,000,000
2,301,866,887
2,552,901,668
2,552,901,668
Net loss per ADS attributed to
ordinary shareholders:
Basic and diluted
–
(9.51)
(4.80)
(0.68)
Weighted average ADS used in
calculating net loss per ADS:
Basic and diluted
–
230,186,689
255,290,167
255,290,167
Net loss
(1,455,694)
(1,808,822)
(1,139,146)
(162,328)
Other comprehensive income/(loss),
net of tax of nil:
Foreign currency translation
adjustments
(35,240)
74,670
(75,858)
(10,810)
Comprehensive loss
(1,490,934)
(1,734,152)
(1,215,004)
(173,138)
Less: comprehensive income/(loss)
attributable to non-controlling interest
20,368
381,363
87,134
12,416
Comprehensive loss attributable to
shareholders of ZEEKR
(1,511,302)
(2,115,515)
(1,302,138)
(185,554)
ZEEKR INC.
UNAUDITED RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS
(Amounts in thousands, except share/ADS and per share/ADS data and otherwise noted)
Three Months Ended
September 30
June 30
September 30
September 30
2023
2024
2024
2024
RMB
RMB
RMB
US$
Loss from operations
(1,507,768)
(1,721,026)
(1,216,371)
(173,332)
Share-based compensation expenses
30,142
943,921
46,595
6,640
Non-GAAP loss from operations
(1,477,626)
(777,105)
(1,169,776)
(166,692)
Net loss
(1,455,694)
(1,808,822)
(1,139,146)
(162,328)
Share-based compensation expenses
30,142
943,921
46,595
6,640
Non-GAAP net loss
(1,425,552)
(864,901)
(1,092,551)
(155,688)
Net loss attributable to ordinary
shareholders
(1,476,062)
(2,190,185)
(1,226,280)
(174,744)
Share-based compensation expenses
30,142
943,921
46,595
6,640
Non-GAAP net loss attributable to
ordinary shareholders of ZEEKR
(1,445,920)
(1,246,264)
(1,179,685)
(168,104)
Weighted average number of
ordinary shares used in calculating
Non-GAAP net loss per share
Basic and diluted
2,000,000,000
2,301,866,887
2,552,901,668
2,552,901,668
Non-GAAP net loss per ordinary
share attributed to ordinary
shareholders
Basic and diluted
(0.72)
(0.54)
(0.46)
(0.07)
Weighted average number of ADS
used in calculating Non-GAAP net
loss per ADS
Basic and diluted
–
230,186,689
255,290,167
255,290,167
Non-GAAP net loss per ADS
attributed to ordinary shareholders
Basic and diluted
–
(5.41)
(4.62)
(0.66)
View original content:https://www.prnewswire.com/news-releases/zeekr-reports-third-quarter-2024-unaudited-financial-results-302305084.html
SOURCE ZEEKR Intelligent Technology Holding Limited
Avathon Partners with CP PLUS, Largest CCTV Manufacturer in India, to Enhance Public Safety while Strengthening Community Bonds
Belgian Unicorn Odoo Celebrates Remarkable First Anniversary in Indonesia
ZEEKR Reports Third Quarter 2024 Unaudited Financial Results
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Peloton Unveils Holiday 2022 Creative Campaign Highlighting How Motivation Transcends Beyond the Workout
These ’90s fashion trends are making a comeback in 2017
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology4 days ago
CloudOne Digital Appoints Packet Cofounder and Former Equinix Executive Zach Smith to Board of Directors to Drive Growth in Bare Metal and Hybrid-Cloud Solutions
-
Coin Market5 days ago
Trump win drives Bitcoin to $76K, PlanB sets $500K target
-
Near Videos5 days ago
Boost Your Yield with Allstake Restaking
-
Near Videos5 days ago
[REDACTED] Day 1 – Reclaim Your Sovereignty
-
Coin Market5 days ago
Norway supports MiCA, considers CBDC for financial stability
-
Coin Market5 days ago
Vitalik explores potential of ‘info finance’ as ETH tops $3K
-
Coin Market5 days ago
A new Trump administration may boost crypto, but the devil is in the details
-
Coin Market5 days ago
Is Helium mining still profitable?